The bradycardia-tachycardia syndrome was treated with pacemaker implantation and drugs in 28 patients.
A tricular tachycardia, the so-called bradycardiatachycardia syndrome, represents a vexing therapeutic problem.' Attempts to control tachyarrhythmias with 8-adrenergic blocking agents and antiarrhythmic drugs may contribute to the severity of the bradyarrhythmias, while the treatment of bradyarrhythmias with ephedrine, belladonna alka-
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loids, or catecholamines may increase the severity of the tachyarrhythrnias. Because of these problems, pacemaker implantation has been combined with antiarrhythmic the rap^.^ However, patients treated in this manner have not had a uniformly good res p o n~e . ~ We have reviewed our own experience in 28 patients with this syndrome to better define factors related to clinical management and prognosis.
Twenty-eight patients with the syndrome of alternating bradycardia and tachycardia were referred to the cardiac catheterization laboratory for consideration of permanent pacemaker implantation. In each case, prior to pacemaker implantation, an attempt was made to control the arrhythmia using pharmacologic agents alone. Patients exhibiting the tachyarrhythmias were usually given digitalis, quinidine, 1 were in NYHA class 1-2; 8 of 9 patients in group 2 were in NYHA class 3-4. Generally, the clinical classification of cardiac status was not changed by treatment. Myocardial infarction, ventricular tachycardia, and primary renal disease were distinctly more common in group 2. Massive myocardial infarctions, both d d and recent, were found at necropsy. It is concluded that: (1) permanent pacemaker implantation, when combined with drug therapy, is effective in the control of the bradycardia-tachycardia syndmme; (2) the prognosis of patients successfuUy treated for the bradycardia-tachycardia syndrome is dependent on the extent of the underlying cardiac and renal disease.
procainamide or propranolol. The bradyarrhythrnias were treated with ephedrine, atropine or belladonna. These medications were administered either parenterally or orally, in progressively increasing dosage, until the occurrence of drug side effects precluded a further increase.
Frequently, pharmacologic therapy was accompanied by insertion of a temporary transvenous pacemaker. After the patient's status stabilized, a fixed rate (Ventricor fixed-rate pacemaker, Cordis Corp.) or R wave coupled (Ectocor demand pacemaker, Cordis Corp.) permanent pacemaker was implanted by the transvenous route.4 In all cases the pacemaker rate was 70 to 72 stimuli per minute. The patients were kept at rest for 12 to 24 hours following the operative procedure, and were discharged from the hospital a t the discretion of the primary physician caring for each patient.
The patients' electrocardiograms were reviewed using standard criteria for left ventricular hypertrophy, left atrial enlargement, bifascicular heart block, and myocardial infarction.5.6 The diagnosis of congestive heart failure and left atrial enlargement was made using clinical and radiologic criteria.6 A diagnosis of aortic stenosis was made on the basis of an ejection systolic murmur at the base, an absent or diminished aortic second sound, a diminished upstroke of the carotid pulse and calcification of the aortic valve on fluoroscopy. A diagnosis of mitral regurgitation was made on the basis of an apical systolic murmur and calcification of the mitral valve or mitral annulus on fluoroscopy. Valvular or coronary calcification was specifically sought on image intensified fluoroscopy at the time of temporary and permanent pacemaker implantation.
The results were analyzed by the chi square method using correction for small numbers. The age data are presented as mean f standard error of the mean.7
Twenty-eight patients with the bradycardiatachycardia syndrome underwent permanent pacemaker implantation. Their clinical data and duration ( 7 percent) failed to achieve a r r h y t h a control following pacemaker implantation as manifested by eight episodes of tachycardia over a mean follow-up period of two months. Despite excellent arrhythmia control, only 19 of the 28 patients were still alive at the end of a mean follow-up period of U) months (32 percent mortality). Nine patients died less than one year following pacemaker implantation (mean survival three months). This latter group includes two patients who failed to respond to combined pacemaker and drug treatment.
To ascertain clinical features of prognostic sign&-cance, the 19 patients surviving longer than one year (group 1) were compared with the nine patients who survived less than one year ( group 2 ) . prised 5 men and 14 women ranging in age from 52 to 88 years, with a mean age of 75 k 5 years. Group 2 comprised five men and four women ranging in age from 72 to 91 years, with a mean age of 79 2 3 years. The incidence of gout, diabetes mellitus, hypertension, and angina pectoris was approximately equal in both groups. Although the occurrence of syncope and angina pectoris during tachyarrhythrnias was equally common in both groups, a history of a prior myocardial infarction was distinctly more common in group 2 ( 8 of 9 ) than in group 1 ( 5 of 19) (p<.01).
The major complaints at the time of pacemaker implantation also are shown in Table 1 . Palpitations and dizziness were present in almost all patients. Approximately two-thirds of the patients had episodes of syncope. In general, this was the most distressing symptom to the patient and was the most frequent symptom bringing the patient to the physician's attention. Angina also was a significant problem in these patients, occurring in 21 percent of the total group, often in association with the tachyarrhythmias. This symptom was more common in group 2 than group 1; however the difference was not statistically significant (P>.10).
Vdwlar Heart Disease
A high incidence of valvular heart disease has been reported in patients with this syndrome.' Review of our cases confirmed this impression and suggested that the presence of aortic stenosis may be an unfavorable prognostic factor. Seven patients had mitral valvular disease and five patients with mitral valvular disease had mitral regurgitation alone. One patient had combined mitral stenosis and regurgitation. Mitral regurgitation was about equally common in both groups, and its presence carried no prognostic significance.
The incidence of aortic stenosis was higher in the poor prognosis group. A single patient in group 1 had aortic stenosis, while this lesion was present in four of nine patients in group 2. None of the patients had evidence of aortic regurgitation.
CLINICAL DATA

History and Major Complaint
The clinical and electrocardiographic features of patients in both groups are summarized in Table 1 . Group 1 arm- Total % l o HB -first degree heart block 2" HB -second degree heart block 3" HB -third degree heart block
Drug Therapy
Prior to pacemaker implantation, pharmacologic therapy was attempted in all cases. In 11 of the 19 patients in group 1 (58 percent) and in eight of the nine patients in group 2 (89 percent) phannacologic treatment alone did not help control the arrhythmias. In the remaining patients in both groups, phannacologic therapy was of some benefit but did not completely control the arrhythmias. Generally, large doses of medications were required and side effects of the drugs necessitated discontinuation before the desired p h m acologic effect d d be achieved. Occasionally, the desired effect of the drug was achieved, but only at doses which either exacerbated the bradyarrhythmias patients being treated for tachvcardia or exacerbated the tachvarrhvthmias . -in patients being treated for bradycardia.
Arrhythmias and Other ECG Features
The incidence of various brady and tachyarrhythmias is summarized in Table 2 . Some degree of atrioventricular block occurred in the majority of the patients in both groups.
Frequently, this followed attempts at control of the tachyarrhythmias using quinidine, procainarnide, digitalis or propranolol. The incidence of the various bradyarrhythmias was not significantly different in the two groups. Atrial fibrillation, paroxysmal atrial tachycardia or atrial flutter with a rapid ventricular response, and junctional tachycardia occurred about equally often in both groups. In contradistinction, ventricular tachycardia was much more common in group 2 (P<.05). Ventricular tachycardia occurred most often as an immediate complication of a rapid supraventricular tachyarrhythmia, although it sometimes occurred independently of the supraventricular tachycardia. In either circumstance, control of ventricular tachycardia was usually effected by pacemaker implantation and antiarrhythmic drugs.
A review of the electrocardiograms of the patients in both groups showed no difference in the incidence of bundle branch block, left anterior hemiblock, or bifascicular block. However, left ventricular hypertrophy was somewhat more common in group 2 ( p < -10 ), and the electrocardiographic pattern of a healed myocardial infarction was significantly more common in group 2 ( p < .01) .
Disease
The results suggest that there was little reversible component to the azotemia seen in these patients (Table 3) . A diagnosis of primary renal disease could be established in almost all patients in group 2 (seven of nine) on the basis of an abnormal urine sediment, positive urine culture, intravenous pyelography or postmortem examination. Evidence of primary renal disease was uncommon among patients in group 1 ( 2 of 19) . This difference in the incidence of primary renal disease was statistically s i d c a n t ( P < .005) and undoubtedly contributed to the poor survival of patients in group 2. with no evidence of loss of pacemaker function. In one patient pacing became ineffective because of an increase in threshold from 0.8 ma to 8.0 ma. This required removal of the pacemaker wire and reimplantation in a new site in the right ventricle where the threshold was 0.5 ma. Fourteen months later, the demand pacemaker was replaced electively. The threshold at that time was 1.0 ma. Ventricular premature depolarizations and competition with the stimulus occurring on the T-wave were occasionally seen in both groups of patients. However, repetitive ventricular responses were not noted. Retrograde capture of the atria was seen in only two patients of each group. In one of these patients, the retrograde atrial capture occurred only intermittently.
Despite the critically-iU state of many of the patients, the surgical procedure was well tolerated and patients were discharged from the hospital on an average of ten days following pacemaker irnplantation.
Four patients in group 1 required replacement of their pacemaker units at intervals of 20 to 31 months (mean 24 months). These four patients had a mean threshold of 0.6 ma at the time of primary implantation and a mean threshold of 1.7 ma at the time of pacemaker replacement. One patient had a rise in
Effect of Pacemaker Implantation on Cardiac Status
Permanent pacemaker implantation resulted in no immediate change in the cardiac status of patients in either group (Table 5 ). Prior to pacemaker implantation congestive heart failure was present in approximately half of the patients in group 1 and all of the patients in group 2 (Table 3 ) . Pacemaker implantation resulted in a decrease in the number of patients in group 1 with congestive heart failure; however, this difference was not statistically significant (p>.05). Patients in group 2 were unimproved despite continued treatment with digitalis, bedrest, and diuretics.
At the time of implantation, the majority of the patients in group 1 were NYSHA class 1 or 2 and the majority of the patients in group 2 were MSHA class 3 or 4. Limitation of activity of these patients was caused by angina pectoris as well as congestive heart failure. Whatever the etiology of their cardiac limitation, a one-to six-month followup of these patients after pacemaker implantation revealed little change in their cardiac status (Table 6 ) .
Complications and Postmortem Examination
Embolization to a systemic artery occurred in 10 percent of patients in group 1 and 45 percent of the patients in group 2. These episodes of embolization occurred both prior to, and following pacemaker implantation. None of these patients was continually treated with anticoagulant drugs.
Five patients were examined postmortem. All five were in group 2. In each case, death was caused by a massive acute myocardial infarction. In addition, there were scars of large old myocardial infarctions In all patients, the pacemaker was properly wedged at the apex of the right ventricle and was well covered by endothelium. There were no perforations of the myocardium and no intracardiac thrombi in the right atrium or right ventricle. In the two patients with pulmonary emboli at necropsy, the source of the emboli was thought to be in the peripheral venous system. None of the patients had evidence of systemic embolization or thrombi within the left atrium or left ventricle.
The original observation of the relationship between sinoatrial heart block and paroxysmal atrial fibrillation was made by Levine in 1916.8 Following this initial observation, there were only sporadic reportss" until demonstration of improved arrhythmia control by pacemaker implantation2 resulted in renewed interest in the bradycardia-tachycardia syndrome. Subsequently, there have been many reports of treatment using pharmacologic agents as well as pacemakers. 12"' The present series represents the largest reported group of patients with the syndrome of brady-and tachyarrhythmias treated by permanent pacemaker implantation. Although the episodes of arrhythmias were controlled in virtually all cases by a combination of pharmacologic therapy and pacemaker insertion, followup has revealed that one-third of the total number of patients died within one year. Several factors may have been responsible for this outcome. First, there were more elderly patients in this series than most other reports. Patients were generally in their seventh or eighth decade and many had severe coronary artery disease and evidence of primary renal disease. Secondly, this series includes only patients with refractory arrhythmias who were referred for pacemaker implantation. In younger patients with thyrotoxicosis or valvular heart disease as the etiology of this syndrome, treatment of the underlying condition may result in excellent arrhythmia control.' As there is an increasing tendency toward aggressive management of older patients with cardiac disease, we believe our experience may be useful in defining the results of combined drug and pacemaker therapy.
At least four factors were identified, which when present, suggested a poor prognosis: ( 1 ) severe limitation of physical activity either because of congestive failure or angina pectoris ( NYHA clinical classification 3 or 4); ( 2 ) valvular heart disease, particularly aortic stenosis, in association with coronary artery disease; ( 3 ) ECG evidence of left ventricular hypertrophy, old myocardial infarction or ventricular tachycardia; and (4) evidence of chronic primary renal disease with a blood urea nitrogen (BUN) level greater than 40 mg percent. Although the patients in group 1 seemed to achieve better arrhythmia control by pharmacologic agents prior to pacemaker implantation than did those in group 2, this difference was not statistically significant (Table  1 ) . Clinical or x-ray film evidence of cardiomegaly, angina pectoris, syncopal episodes, diabetes mellitus, and a history of hypertension seemed to be equally common in patients surviving for more than one year ( group 1 ) , and those surviving for less than one year (group 2), hence, were of little prognostic value.
An increased incidence of valvular heart disease was reported previously in patients with the bradycardia-tachycardia syndrome.1.3.8.20.23,28~27 While mitral valvular disease was equally common in both groups of patients, aortic valvular disease was significantly more common in the patients in group 2. None of these patients was thought to have critically tight aortic stenosis on clinical grounds. At necropsy none of the patients had aortic valve areas measuring less than 0.5 ~m .~ Thus, the poor prognosis observed in patients with aortic stenosis could not be directly attributed to the hemodynamic consequences of this lesion.
ECG evidence of prior myocardial infarction, left ventricular hypertrophy or the occurrence of ventricular tachycardia were both poor prognostic signs. While improving our ability to apply effective antiarrhythmic therapy, pacemaker implantation has failed to prevent the early death of patients with prior episodes of ventricular tachycardia. These patients have died of the inexorable progress of their coronary artery disease. All patients dying within one year of pacemaker implantation, in whom postmortem data were available, had evidence of ad-
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vanced coronary artery atherosclerosis, with extensive old and recent myocardial infarctions. Elevation of blood urea nitrogen levels above 40 mg percent at the time of pacemaker implantation was a striking sign of poor prognosis. None of the deaths could be attributed directly to primary renal disease. Rather, the intrinsic abnormalities in renal function seemed to be exaggerated by a poorly compensated cardiovascular system.
There are a number of electrophysiologic factors involved in the rapid alteration that occurs between tachyarrhythmias and bradyarrhythmias. Since the period of sinus node suppression following ectopic tachyarrhythrmas is directly proportional to the rate of the preceding t a c h y~a r d i a~~.~~ and to sinus node function,34 it is not surprising that the cessation of paroxysmal atrial tachyarrhythmias may be accompanied by varying periods of asystole.
Treatment of tachyarrhythmia with quinidine, procainamide, digitalis or p-blocking agents may increase the asystolic interval following tachycardia. Moreover, bradyarrhythmias are known to result not only in dispersion of the refractory period^,^ but also in a greater opportunity for an ectopic pacemaker focus to d i s~h a r g e .~~
Both factors are conducive to the development of a reentrant tachyarrhythmia.
In isolated cases, pacemaker implantation with retrograde capture of the atria has reversed the propensity toward the development of a supraventricular tachycardia, and it has been suggested that pacemaker implantation alone may be adequate therapy in these instance^.^^^^*^^ Although retrograde atrial capture during ventricular pacing is noted in a high percentage of normal s~bjects,~' we have observed ventriculoatrial conduction in only 14 percent of our patients. It should be noted that retrograde excitation may be confined to A-V junctional tissue without progressing to the atrium. It is possible that ventricular pacing by this mechanism may help to abort junctional tachycardias or reentrant tachycardias originating from the A-V junct i~n .~~ However, in our experience electrical pacing as the sole therapy did not control arrhythmias in all patients with the bradycardia-tachycardia syndrome. Therefore we have treated patients with drugs as well as pacemaker implantation. The pacemaker acts to prevent serious bradyarrhythmias and allows treatment with larger doses of antiarrhythmic agents.
Atrial or A-V sequential pacing may offer s i dcant advantages in controlling the arrhythmias which may occur in the bradycardia-tachycardia syndrome. This mode of therapy has not been utilized in our patients because of the prevalence of A-V conduction abnormalities, and the diminished longevity and reliability of the A-V sequential pacemaker. When this problem is solved, demand A-V sequential pacing may represent an ideal method of controlling this syndrome while preserving the hernodynamic advantage of atrial pacing.
Because of the distressing symptomatology of this syndrome, patients with the bradycardia-tachycardia syndrome require as complete control of their arrhythmias as possible, potentially reversible etiologic factors such as digitalis toxicity, hyperthyroidism or operable valvular heart disease should be diligently sought. However, in patients beyond the seventh decade, the majority of patients have severe coronary artery disease as the underlying etiology.
Treatment with drugs in these patients is often ineffective. An occasional patient may be managed with full doses of digitalk3' While addition of suppressive agents (such as quinidine or procainamide) may improve control of the tachyarrhythmia, these agents often exacerbate bradyarrhythmias. Betaadrenergic blocking agents not only tend to exacerbate bradyarrhythmias, but must be used with extreme caution if there is preexisting congestive heart failure. Because of these disadvantages, it is our recommendation that permanent pacemaker implantation should be carried out prior to use of suppressive agents and that p-adrenergic blockers be used only if other antiarrhythmics fail. Using this program, almost all patients can be maintained totally free of further episodes of tachycardia or bradycardia. In our experience, discontinuation of antiarrhythmic agents after pacemaker implantation has resulted in recurrence of the tachyarrhythmia and, hence, should be avoided.
Systemic embolization occurred in 21 percent of our patients. The high frequency of this complication which also has been noted recently by others3' generally has not received sufficient emphasis. Despite the possible increased risk of acute cardiac tamponade should myocardial perforation by the pacemaker electrode occur, it is our recommendation at present that continuous therapy with anticoagulants should be considered in the absence of a strong contraindication. Abnormalities of renal function noted in our patients were not so severe as to contraindicate continual use of anticoagulant therapy. However, the incidence of bleeding episodes may be increased. Agents such as salicylates and dipyridamole, which have been shown to diminish arterial embolization in patients with prosthetic valves,39 may be useful in this syndrome as well.
